{'fraction_non_alphanumeric': 0.029781601588352084, 'fraction_numerical': 0.024487094639311716, 'mean_word_length': 5.096774193548387, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Gadolinium-Based Magnetic Ionic Liquid for Supramolecular Dispersive Liquid-Liquid Microextraction Followed by HPLC/UV for Determination of Favipiravir in Human Plasma.

Favipiravir is a potential antiviral medication that has been recently licensed for COVID-19 treatment. In this work, a gadolinium based magnetic ionic liquid was prepared and used as an extractant in dispersive liquid-liquid microextraction (DLLME) of favipiravir in human plasma. The high enriching ability of DLLME allowed determination of favipiravir in real samples using HPLC/UV with sufficient sensitivity. The effects of several variables on extraction efficiency were investigated, including type of extractant, amount of extractant, type of disperser and disperser volume. The maximum enrichment was attained using 50mg of the Gd-MIL and 150μL of tetrahydrofuran. The Gd-based MIL could form a supramolecular assembly in the presence of tetrahydrofuran, which enhanced the extraction efficiency of favipiravir. The developed method was validated according to FDA bioanalytical method validation guidelines. The coefficient of determination was found to be 0.9999, for a linear concentration range of 25 to 1.0 × 105 ng/mL. The percent recovery (accuracy) varied from 99.83 to 104.2 %, with % RSD values (precision) ranging from 4.07 to 11.84 %. Total extraction time was about 12 min and the HPLC analysis time was 5 min. The method was found simple, selective and sensitive for determination of favipiravir in real human plasma.